At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Post-Mkt 10-16 16:11:37 EDT
18.03
-1.31
-6.77%
盘后18.03
+0.000.00%
16:10 EDT
High19.45Low18.00Vol720.17K
Open19.45D1 Closing19.34Amplitude7.50%
Mkt Cap1.07BTradable Cap671.32MTotal Shares59.16M
T/O13.20MT/O Rate1.93%Tradable Shares37.23M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Citi Sticks to Its Buy Rating for Vor Biopharma (VOR)
TIPRANKS  ·  10-15 19:56
Citi Sticks to Its Buy Rating for Vor Biopharma (VOR)
How Investors May Respond To Vor Biopharma (VOR) Phase 3 gMG Data
Simply Wall St.  ·  10-12
How Investors May Respond To Vor Biopharma (VOR) Phase 3 gMG Data
Vor Bio Grants Inducement Stock Options for 59,250 Shares, RSUs for 12,550 Shares to New Hires
Reuters  ·  10-06
Vor Bio Grants Inducement Stock Options for 59,250 Shares, RSUs for 12,550 Shares to New Hires
Vor Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-06
Vor Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Long Lasting Symptom Relief Data Could Be A Game Changer For Vor Biopharma Stock
Simply Wall St.  ·  10-05
Long Lasting Symptom Relief Data Could Be A Game Changer For Vor Biopharma Stock
U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle
Reuters  ·  09-29
U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle
US Stocks on the MOVE-Veracyte, Staar Surgical, Corning
Reuters  ·  09-29
US Stocks on the MOVE-Veracyte, Staar Surgical, Corning
Vor Biopharma Rises After Positive Autoimmune Drug Data
Reuters  ·  09-29
Vor Biopharma Rises After Positive Autoimmune Drug Data
Vor Bio Says Telitacicept Phase 3 Analysis Shows 42% Minimal Symptom Expression in gMG Through 48 Weeks
Reuters  ·  09-29
Vor Bio Says Telitacicept Phase 3 Analysis Shows 42% Minimal Symptom Expression in gMG Through 48 Weeks
Vor Biopharma Inc: More than 94% of Participants Achieved a ≥5-Point Mg-Adl Improvement at Week 48
THOMSON REUTERS  ·  09-29
Vor Biopharma Inc: More than 94% of Participants Achieved a ≥5-Point Mg-Adl Improvement at Week 48
Vor Biopharma Inc: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
THOMSON REUTERS  ·  09-29
Vor Biopharma Inc: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Vor Biopharma Inc: Telitacicept was Generally Well Tolerated Through 48 Weeks with no New Safety Signals Observed
THOMSON REUTERS  ·  09-29
Vor Biopharma Inc: Telitacicept was Generally Well Tolerated Through 48 Weeks with no New Safety Signals Observed
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
TIPRANKS  ·  09-28
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
Citi Keeps Their Buy Rating on Vor Biopharma (VOR)
TIPRANKS  ·  09-10
Citi Keeps Their Buy Rating on Vor Biopharma (VOR)
Vor Bio completes enrollment in UPSTREAM MG trial
TIPRANKS  ·  09-08
Vor Bio completes enrollment in UPSTREAM MG trial
Vor Bio Completes Enrollment in Phase 3 Upstream MG Trial for Telitacicept in Generalized Myasthenia Gravis
Reuters  ·  09-08
Vor Bio Completes Enrollment in Phase 3 Upstream MG Trial for Telitacicept in Generalized Myasthenia Gravis
Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
THOMSON REUTERS  ·  09-08
Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Vor Biopharma - Upstream Mg 24-Week Primary Endpoint Results Expected in First Half of 2027
THOMSON REUTERS  ·  09-08
Vor Biopharma - Upstream Mg 24-Week Primary Endpoint Results Expected in First Half of 2027
Vor Bio files automatic mixed securities shelf
TIPRANKS  ·  09-05
Vor Bio files automatic mixed securities shelf
Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing
THOMSON REUTERS  ·  09-05
Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--